MedTrace Logo

A Post-marketing Research on Jinyebaidu Granule in Treating Patients With Acute Upper Respiratory Infection

NCT02539277 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2015-09-03

No results posted yet for this study

Summary

Study topic：A comparative effectiveness research on Jinyebaidu granule in treating patients with acute upper respiratory infection: A double blind, double dummy, randomized, controlled trial. It is a post-marketing clinical study to evaluate effectiveness, safety and cost-effectiveness on Jinyebaidu granule in treating acute upper respiratory infection.

Objectives of Study：This study aims to evaluate effectiveness, safety and cost-effectiveness on Jinyebaidu granule in treating patients with acute upper respiratory infection.

Study design：multi-center double-blind, double-dummy, randomized, controlled trial

Conditions

  • Acute Upper Respiratory Infection

Interventions

DRUG

Jinyebaidu granule

It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.

DRUG

Fufangshuanghua granule

It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.

DRUG

Jinyebaidu granule placebo

It is Jinyebaidu granule placebo.

DRUG

Fufangshuanghua granule placebo

It is Fufangshuanghua granule placebo.

Sponsors & Collaborators

  • First Affiliated Hospital of Heilongjiang Chinese Medicine University

    collaborator OTHER

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    collaborator OTHER

  • Beijing Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Changchun University of Chinese Medicine

    collaborator OTHER

  • Liaoning University of Traditional Chinese Medicine

    collaborator OTHER

  • Shandong University of Traditional Chinese Medicine

    collaborator OTHER

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Yanming Xie · Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02539277 on ClinicalTrials.gov